LOG IN
SIGN UP
MARKET
CNCE
CNCE
Concert Pharm
NASDAQ
Real-time Quotes | Nasdaq Last Sale
6.27
+1.25
+24.95%
Opening 11:41 05/27 EDT
OPEN
5.26
PREV CLOSE
5.02
HIGH
6.50
LOW
5.26
VOLUME
2.72M
TURNOVER
9.49M
52 WEEK HIGH
6.50
52 WEEK LOW
2.570
MARKET CAP
227.87M
P/E (TTM)
-2.3534
1D
5D
1M
3M
1Y
5Y
FTCH, CNCE and LQDA among pre market gainers
Dollar Tree DLTR +17% on Q1 results. Build-A-Bear Workshop BBW +17% on Q1 results. Destination XL DXLG +15% on Q1 results. Joby Aviation JOBY +15% after receipt of FAA Part 135 Air Carrier Certificate. Macy's M +14% on Q1 results.
Seekingalpha · 1d ago
The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma
Benzinga · 3d ago
Concert Pharma's CTP-543 Shows Clinical Efficacy Against Scalp Hair Loss
Benzinga · 4d ago
BRIEF-Concert Pharmaceuticals Reports Positive Topline Results For First CTP-543 Phase 3 Clinical Trial
reuters.com · 4d ago
Concert's CTP-543 helps hair regrowth in alopecia areata patients, meets trial's main goal
Concert Pharmaceuticals (NASDAQ:CNCE) said a phase 3 trial of its oral drug CTP-543 met the main goal of scalp hair regrowth at both doses in patients with moderate to severe
Seekingalpha · 4d ago
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
LEXINGTON, Mass., May 23, 2022--Concert's THRIVE-AA1 Phase 3 study in alopecia areata meets primary endpoint for scalp hair regrowth and key secondary endpoints at both doses.
Business Wire · 4d ago
Concert Pharmaceuticals Says its Alopecia Areata Investigational Drug CTP-543 Met Phase 3 Trial Endpoints
MT Newswires · 4d ago
Celularity, Purple Biotech top healthcare gainers; Baudax Bio, Doximity lead losers' pack
Gainers: Celularity CELU +10%. Purple Biotech (PPBT) +8%. BioSig Technologies (BSGM) +4%. Concert Pharmaceuticals (CNCE) +4%. Molecular Partners (MOLN) +4%. Losers: Baudax Bio BXRX -28%. Doximity DOCS -9%. Radius Health (RDUS) -7%. NextGen Healthcare (NXGN...
Seekingalpha · 05/18 14:05
No Data
Learn about the latest financial forecast of CNCE. Analyze the recent business situations of Concert Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 6 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
16.67%Strong Buy
83.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CNCE stock price target is 13.08 with a high estimate of 22.00 and a low estimate of 9.00.
Current 6.32
EPS
Actual
Estimate
-0.78-0.54-0.29-0.05
Institutional Holdings
Institutions: 91
Institutional Holdings: 19.45M
% Owned: 53.55%
Shares Outstanding: 36.33M
TypeInstitutionsShares
Increased
12
596.62K
New
9
2.78M
Decreased
21
1.27M
Sold Out
19
1.52M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.09%
Pharmaceuticals & Medical Research
+0.50%
Key Executives
Non-Executive Chairman/Independent Director
Richard Aldrich
President/Chief Executive Officer/Co-Founder/Director
Roger Tung
Chief Financial Officer
Marc Becker
Chief Operating Officer
Nancy Stuart
Other
James Cassella
Secretary
Jeffrey Munsie
Independent Director
Thomas Auchincloss
Independent Director
Ronald Barrett
Independent Director
Jesper Hoiland
Independent Director
Peter Hutt
Independent Director
Wilfred Jaeger
Independent Director
Christine van Heek
No Data
No Data
About CNCE
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing small molecule drugs that are discovered through the application of its deuterated chemical entity platform, DCE Platform. Its DCE Platform drives enables the Company to design drug candidates to create differentiated properties and address patient needs. The Company’s lead product candidate, CTP-543, which it is evaluating in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. CTP-543 was discovered by applying its deuterium chemistry technology to modify ruxolitinib, a Janus kinase, or JAK, inhibitor, which is commercially available under the name Jakafi in the United States for the treatment of certain blood disorders and for graft versus host disease. The Company is also assessing a number of earlier-stage pipeline candidates.
Webull offers kinds of Concert Pharmaceuticals Inc stock information, including NASDAQ:CNCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNCE stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading CNCE stock methods without spending real money on the virtual paper trading platform.